Clinical Trial Update: Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial studying vandetanib combined with metformin in patients with hereditary leiomyomatosis-related renal cell carcinoma (HLRCC) or SDH-associated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Leiomyomatosis
• Papillary Renal Cell Carcinoma
• Renal Cell Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Vandetanib (vandetanib)
• metformin (metformin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Renal Cell Carcinoma, Hereditary Leiomyomatosis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-01-26